Two-day testing for antibodies in plasma begins at CFTRI
Coronavirus Update, COVID-19, News

Two-day testing for antibodies in plasma begins at CFTRI

September 15, 2020

Mysore/Mysuru: As part of the nationwide project from CSIR- IGIB (CSIR-Institute of Genomics & Integrative Biology), New Delhi, a two-day Pan-CSIR Phenome India Sero Surveillance for COVID-19, began at CSIR- Central Food Technological Research Institute (CFTRI) in city this morning.

This is being conducted for all staff and students of CFTRI.  CFTRI Director Dr. R. Subramanian was the first to participate and provide blood sample for the clinical study.

Project Member Dr. P.V. Ravindra, speaking to Star of Mysore, said that this testing is being carried out at all CSIR institutes across the country to verify the prevalence of COVID-19 in the population based on the estimation of antibodies in the plasma.

He further said that it also provided information about the immune status of the individual. 

Project Leader Dr. Shantanu Sengupta of CSIR-IGIB, New Delhi, Co-ordinator Dr. Prakash M. Halami, Members Dr. Muthukumar, Dr. M.S. Gopinath, Dr. Avilash and others were present. 


Mysuru’s favorite and largest circulated English evening daily has kept the citizens of Mysuru informed and entertained since 1978. Over the past 45 years, Star of Mysore has been the newspaper that Mysureans reach for every evening to know about the happenings in Mysuru city. The newspaper has feature rich articles and dedicated pages targeted at readers across the demographic spectrum of Mysuru city. With a readership of over 2,50,000 Star of Mysore has been the best connection between it’s readers and their leaders; between advertisers and customers; between Mysuru and Mysureans.


Academy News Papers Private Limited, Publishers, Star of Mysore & Mysuru Mithra, 15-C, Industrial ‘A’ Layout, Bannimantap, Mysuru-570015. Phone no. – 0821 249 6520

To advertise on Star of Mysore, email us at

Online Edition: [email protected]
Print Editon: [email protected]
For News/Press Release: [email protected]